EKF Diagnostics Holdings plc

("EKF" or the "Company")

Total Voting Rights

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics business, refers to its announcement dated 23 March 2023 regarding the disposal of Advanced Diagnostic Laboratory LLC ("ADL Health") (the "Disposal").

Part of the consideration for ADL Health comprised the return of 1,200,000 ordinary shares of 1p each in the capital of the Company ("Ordinary Shares") which had originally been issued as part of the payment made to the vendors of ADL Health when it was acquired by EKF in 2021. The Company now confirms that these 1,200,000 Ordinary Shares have now been received by EKF and are being held in treasury.

As a result, the Company's total issued share capital now consists of 454,930,564 Ordinary Shares with one voting right per share. The Company holds 1,200,000 Ordinary Shares in treasury. The total number of voting rights in the Company is therefore 453,730,564.

The above figure of 453,730,564 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.

About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com)

EKF is an AIM-listed global diagnostics business focussed on:

·    Point-of-Care analysers in the key areas of Hematology and Diabetes, as well as Central Laboratory products including clinical chemistry reagents, analysers and centrifuges

·    Life Sciences services provide specialist manufacture of enzymes and custom products for use in diagnostic food and industrial applications, as well as other higher value Contract Manufacturing services

EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.